J Korean Med Assoc.  2004 Nov;47(11):1075-1098. 10.5124/jkma.2004.47.11.1075.

Community Acquired Pneumonia

• Chang J

• KMID: 1957921
• DOI: http://doi.org/10.5124/jkma.2004.47.11.1075

Abstract

Community acquired pneumonia is a common disease, and it is usually managed by empirical antibiotics therapy from several management guidelines. It is challenged by emergence of drug resistant bacterial strains, especially Streptococcus pneumoniae and recent increasing recognition for the mixed infection by atypical pneumonia pathogens such as Mycoplasma, Chlamydia and Legionella species. Even though community acquired pneumoniae caused by drug resistant S. pneumoina is common in Korea, the treatment results are good with current antibiotics. This review deals with important new findings and management issues of community acquired pneumonia in immunocompetent adults.

Keyword

Community acquired pneumonia

MeSH Terms

Adult
Anti-Bacterial Agents
Chlamydia
Coinfection
Humans
Korea
Legionella
Mycoplasma
Pneumonia*
Streptococcus pneumoniae
Anti-Bacterial Agents

Reference

1. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993. 148:1418–1426.

2. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia:Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001. 163:1730–1754.

3. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults:Guideline from the Infectious Diseases Society of America. Clin Infect Dis. 2000. 31:347–382.

4. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. IDSA guidelines. Clin Infect Dis. 2003. 37:1405–1433.

5. Swartz MN. Fishman AP, Elias JA, editors. Approach to the patient with pulmonary infections. Fishman's Pulmonary diseases and disorders. 1998. 3rd ed. New York: McGraw-Hill;1905–1937.

6. Donowitz GR, Mandell GL. Mandell GL, Bennet JE, Dolin R, editors. Acute pneumonia. Principles and practice of infectious diseases. 1995. 4th ed. New York: Churchill Livingstone;619–637.

7. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995. 333:1618–1624.

8. Pomilla PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med. 1994. 154:1793–1802.

9. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet. 1998. 352:1295–1302.

12. Stout JE, Yu VL. Legionellosis. N Engl J Med. 1997. 337:682–687.

13. Sanford JP, Gilbert DN, Sande MA. The Sanford guide to antimicrobial therapy. 1999. 29th ed. Vienna(VA, USA): Antimicrobial Therapy Inc..

16. Choi EH, Lee HJ. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae. Clin Infect Dis. 1998. 26:1346–1354.

17. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, So T, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries:a study by the Asian network for surveillance of resistant pathogens. Clin Infect Dis. 2004. 38:1570–1578.

18. Feldman C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med. 2004. 143:269–283.